Loading…
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5)...
Saved in:
| Published in: | Acta biochimica et biophysica Sinica 2009-05, Vol.41 (5), p.429-435 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03 |
| container_end_page | 435 |
| container_issue | 5 |
| container_start_page | 429 |
| container_title | Acta biochimica et biophysica Sinica |
| container_volume | 41 |
| creator | Feng, Jifeng Sun, Xinchen Sun, Ning Qin, Shukui Li, Fan Cheng, Hongyan Chen, Baoan Cao, YuanDong Ma, Jun Cheng, Lu Lu, Zuhong Ji, Jiazhong Zhou, Yingfeng |
| description | DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant. |
| doi_str_mv | 10.1093/abbs/gmp027 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67218468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/abbs/gmp027</oup_id><sourcerecordid>67218468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03</originalsourceid><addsrcrecordid>eNp9kEtLxDAURoMovlfuJSs3Ur1p2sQsB_EFgi4U3JUkTZ1K08TcdmT2_nA7zoA7N7nhfocv4RBywuCCgeKX2hi8fPcRcrlF9pksykzmEranu5B5plhR7pEDxA8ALgSDXbLHVMFBgtgn32_PMzrL-R2NoVv6kOK8RU9bpBox2FYPrqZf7TCnw9xR17nF7yY5jKFHR4dAY6eHth99ZjROkZ07HyY46bikbU91vdC9nYI-9Bl63XXUuunoxv6d2lWUjshOozt0x5t5SF5vb16u77PHp7uH69ljZnlZDlmRN4obxVkDTEoolSprW7OmBm2YMw032jEoJFhjci644oUQQjVcF6DAAD8kZ-vemMLn6HCofIurz-jehRGrSRe7KsTVBJ6vQZsCYnJNFVPrdVpWDKqV9GolvVpLn-jTTe1ovKv_2I3lv3fDGP9t-gGSEozR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67218468</pqid></control><display><type>article</type><title>XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Feng, Jifeng ; Sun, Xinchen ; Sun, Ning ; Qin, Shukui ; Li, Fan ; Cheng, Hongyan ; Chen, Baoan ; Cao, YuanDong ; Ma, Jun ; Cheng, Lu ; Lu, Zuhong ; Ji, Jiazhong ; Zhou, Yingfeng</creator><creatorcontrib>Feng, Jifeng ; Sun, Xinchen ; Sun, Ning ; Qin, Shukui ; Li, Fan ; Cheng, Hongyan ; Chen, Baoan ; Cao, YuanDong ; Ma, Jun ; Cheng, Lu ; Lu, Zuhong ; Ji, Jiazhong ; Zhou, Yingfeng</creatorcontrib><description>DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.</description><identifier>ISSN: 1672-9145</identifier><identifier>EISSN: 1745-7270</identifier><identifier>DOI: 10.1093/abbs/gmp027</identifier><identifier>PMID: 19430706</identifier><language>eng</language><publisher>China: Oxford University Press</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Cisplatin - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; DNA-Binding Proteins - genetics ; Docetaxel ; Endonucleases - genetics ; Female ; Gene Frequency ; Genotype ; Humans ; Logistic Models ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Nuclear Proteins - genetics ; Paclitaxel - administration & dosage ; Polymorphism, Single Nucleotide ; Taxoids - administration & dosage ; Transcription Factors - genetics ; Treatment Outcome ; Vinblastine - administration & dosage ; Vinblastine - analogs & derivatives ; Vinorelbine ; Xeroderma Pigmentosum Group A Protein - genetics]]></subject><ispartof>Acta biochimica et biophysica Sinica, 2009-05, Vol.41 (5), p.429-435</ispartof><rights>The Author 2009. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03</citedby><cites>FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19430706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feng, Jifeng</creatorcontrib><creatorcontrib>Sun, Xinchen</creatorcontrib><creatorcontrib>Sun, Ning</creatorcontrib><creatorcontrib>Qin, Shukui</creatorcontrib><creatorcontrib>Li, Fan</creatorcontrib><creatorcontrib>Cheng, Hongyan</creatorcontrib><creatorcontrib>Chen, Baoan</creatorcontrib><creatorcontrib>Cao, YuanDong</creatorcontrib><creatorcontrib>Ma, Jun</creatorcontrib><creatorcontrib>Cheng, Lu</creatorcontrib><creatorcontrib>Lu, Zuhong</creatorcontrib><creatorcontrib>Ji, Jiazhong</creatorcontrib><creatorcontrib>Zhou, Yingfeng</creatorcontrib><title>XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer</title><title>Acta biochimica et biophysica Sinica</title><addtitle>Acta Biochim Biophys Sin (Shanghai)</addtitle><description>DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cisplatin - administration & dosage</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Docetaxel</subject><subject>Endonucleases - genetics</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genotype</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nuclear Proteins - genetics</subject><subject>Paclitaxel - administration & dosage</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Taxoids - administration & dosage</subject><subject>Transcription Factors - genetics</subject><subject>Treatment Outcome</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vinorelbine</subject><subject>Xeroderma Pigmentosum Group A Protein - genetics</subject><issn>1672-9145</issn><issn>1745-7270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAURoMovlfuJSs3Ur1p2sQsB_EFgi4U3JUkTZ1K08TcdmT2_nA7zoA7N7nhfocv4RBywuCCgeKX2hi8fPcRcrlF9pksykzmEranu5B5plhR7pEDxA8ALgSDXbLHVMFBgtgn32_PMzrL-R2NoVv6kOK8RU9bpBox2FYPrqZf7TCnw9xR17nF7yY5jKFHR4dAY6eHth99ZjROkZ07HyY46bikbU91vdC9nYI-9Bl63XXUuunoxv6d2lWUjshOozt0x5t5SF5vb16u77PHp7uH69ljZnlZDlmRN4obxVkDTEoolSprW7OmBm2YMw032jEoJFhjci644oUQQjVcF6DAAD8kZ-vemMLn6HCofIurz-jehRGrSRe7KsTVBJ6vQZsCYnJNFVPrdVpWDKqV9GolvVpLn-jTTe1ovKv_2I3lv3fDGP9t-gGSEozR</recordid><startdate>200905</startdate><enddate>200905</enddate><creator>Feng, Jifeng</creator><creator>Sun, Xinchen</creator><creator>Sun, Ning</creator><creator>Qin, Shukui</creator><creator>Li, Fan</creator><creator>Cheng, Hongyan</creator><creator>Chen, Baoan</creator><creator>Cao, YuanDong</creator><creator>Ma, Jun</creator><creator>Cheng, Lu</creator><creator>Lu, Zuhong</creator><creator>Ji, Jiazhong</creator><creator>Zhou, Yingfeng</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200905</creationdate><title>XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer</title><author>Feng, Jifeng ; Sun, Xinchen ; Sun, Ning ; Qin, Shukui ; Li, Fan ; Cheng, Hongyan ; Chen, Baoan ; Cao, YuanDong ; Ma, Jun ; Cheng, Lu ; Lu, Zuhong ; Ji, Jiazhong ; Zhou, Yingfeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cisplatin - administration & dosage</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Docetaxel</topic><topic>Endonucleases - genetics</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genotype</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nuclear Proteins - genetics</topic><topic>Paclitaxel - administration & dosage</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Taxoids - administration & dosage</topic><topic>Transcription Factors - genetics</topic><topic>Treatment Outcome</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vinorelbine</topic><topic>Xeroderma Pigmentosum Group A Protein - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feng, Jifeng</creatorcontrib><creatorcontrib>Sun, Xinchen</creatorcontrib><creatorcontrib>Sun, Ning</creatorcontrib><creatorcontrib>Qin, Shukui</creatorcontrib><creatorcontrib>Li, Fan</creatorcontrib><creatorcontrib>Cheng, Hongyan</creatorcontrib><creatorcontrib>Chen, Baoan</creatorcontrib><creatorcontrib>Cao, YuanDong</creatorcontrib><creatorcontrib>Ma, Jun</creatorcontrib><creatorcontrib>Cheng, Lu</creatorcontrib><creatorcontrib>Lu, Zuhong</creatorcontrib><creatorcontrib>Ji, Jiazhong</creatorcontrib><creatorcontrib>Zhou, Yingfeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta biochimica et biophysica Sinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feng, Jifeng</au><au>Sun, Xinchen</au><au>Sun, Ning</au><au>Qin, Shukui</au><au>Li, Fan</au><au>Cheng, Hongyan</au><au>Chen, Baoan</au><au>Cao, YuanDong</au><au>Ma, Jun</au><au>Cheng, Lu</au><au>Lu, Zuhong</au><au>Ji, Jiazhong</au><au>Zhou, Yingfeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer</atitle><jtitle>Acta biochimica et biophysica Sinica</jtitle><addtitle>Acta Biochim Biophys Sin (Shanghai)</addtitle><date>2009-05</date><risdate>2009</risdate><volume>41</volume><issue>5</issue><spage>429</spage><epage>435</epage><pages>429-435</pages><issn>1672-9145</issn><eissn>1745-7270</eissn><abstract>DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.</abstract><cop>China</cop><pub>Oxford University Press</pub><pmid>19430706</pmid><doi>10.1093/abbs/gmp027</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1672-9145 |
| ispartof | Acta biochimica et biophysica Sinica, 2009-05, Vol.41 (5), p.429-435 |
| issn | 1672-9145 1745-7270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67218468 |
| source | PubMed Central; EZB Electronic Journals Library |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives DNA-Binding Proteins - genetics Docetaxel Endonucleases - genetics Female Gene Frequency Genotype Humans Logistic Models Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Nuclear Proteins - genetics Paclitaxel - administration & dosage Polymorphism, Single Nucleotide Taxoids - administration & dosage Transcription Factors - genetics Treatment Outcome Vinblastine - administration & dosage Vinblastine - analogs & derivatives Vinorelbine Xeroderma Pigmentosum Group A Protein - genetics |
| title | XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A49%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=XPA%20A23G%20polymorphism%20is%20associated%20with%20the%20elevated%20response%20to%20platinum-based%20chemotherapy%20in%20advanced%20non-small%20cell%20lung%20cancer&rft.jtitle=Acta%20biochimica%20et%20biophysica%20Sinica&rft.au=Feng,%20Jifeng&rft.date=2009-05&rft.volume=41&rft.issue=5&rft.spage=429&rft.epage=435&rft.pages=429-435&rft.issn=1672-9145&rft.eissn=1745-7270&rft_id=info:doi/10.1093/abbs/gmp027&rft_dat=%3Cproquest_cross%3E67218468%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c355t-42f93b931f017705995dcd1fd0ab1ebf3bae10470cbb23639346669f3a4090b03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67218468&rft_id=info:pmid/19430706&rft_oup_id=10.1093/abbs/gmp027&rfr_iscdi=true |